Geron (NASDAQ:GERN) stock is heading higher on Friday after getting approval from the Food and Drug Administration (FDA) for RYTELO. RYTELO is the company’s “adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent (TD) anemia.” This is a blood cancer that often leaves patients with anemia, fatigue and shortened survival periods. Rami Komrokji, MD, an investigator in the RYTELO clinical trials, said the following about the approval. “What is exciting about R ...